<DOC>
	<DOCNO>NCT02615106</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy Radiotherapy plus Endostar ( Recombinant Human Endostatin ) patient Pediatric Neuroblastoma .</brief_summary>
	<brief_title>Anti-angiogenetic Therapy With Radiotherapy Pediatric Neuroblastoma</brief_title>
	<detailed_description>Clinical data prove Endostar wild spectrum safe antiangiogenesis factor could suppress almost 65 kind tumor mass animal model affect 12 percent human genome . So investigators design Radiotherapy plus Endostar treat Pediatric Neuroblastoma research RR safety . Investigators believe treatment regimen may new approach pediatric neuroblastoma patient .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Endostatins</mesh_term>
	<criteria>Participants must histologically confirm neuroblastoma ganglioneuroblastoma elevate urinary catecholamine metabolite . Life expectancy great 12 month . ECOG performance status ≤2 Diagnostic Imaging MRI and/or CT area treat within 8 week treatment . Baseline bone marrow biopsy bone scan ( 99mTcdiphosphonate MIBG scan ( 131IMIBG 123IMIBG ) time original diagnosis require . Because radiation know teratogenic , woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . Ability patient patient 's legal guardian understand willingness sign write informed consent document . Participants legal guardian must sign consent prior initiation radiation therapy . Patients ineligible prior therapeutic radiation therapy &gt; 500 cGy deliver . Patients ineligible chemotherapy complete ≥ 1 year plan start date radiation therapy patient refer radiation therapy relapse follow regimen chemotherapy alone . Individuals history different malignancy ineligible except follow circumstance . Individuals history malignancy eligible diseasefree least 5 year deem investigator low risk recurrence malignancy . Individuals follow cancer eligible diagnose treat within past 5 year : cervical cancer situ , basal cell squamous cell carcinoma skin . Pregnant female exclude . Women childbearing age/menstruating must negative pregnancy test prior initiation radiation therapy .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Radiation Therapy</keyword>
	<keyword>Neuroblastoma</keyword>
</DOC>